PREDICTORS FOR LOCOREGIONAL RECURRENCE AFTER RADICAL PROSTATECTOMY


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

An analysis of domestic and foreign literature on the predictors of prostate cancer recurrence are presented in the article. A deep analysis of both pathological and histological risk factors for progression was provided, as well as of laboratory and clinical predictors.

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Petrovskij

FGAOU VO I.M. Sechenov First Moscow State Medical Universit

Email: n_petrovskiy@hotmail.com
Ph.D., associate professor at the Institute of Urology and Reproductive Health Moscow, Russia

G. Krupinov

FGAOU VO I.M. Sechenov First Moscow State Medical Universit

Email: gekrupinov@mail.ru
Ph.D., MD, associate professor, professor Institute of Urology and Reproductive Health Moscow, Russia

A. Amosov

FGAOU VO I.M. Sechenov First Moscow State Medical Universit

Email: amosov-av@yandex.ru
Ph.D., MD, professor Institute of Urology and Reproductive Health Moscow, Russia

D. Chinenov

FGAOU VO I.M. Sechenov First Moscow State Medical Universit

Email: chinenovdv@rambler.ru
Ph.D., associate professor Institute of Urology and Reproductive Health Moscow, Russia

N. Gerasimenko

FGAOU VO I.M. Sechenov First Moscow State Medical Universit

Email: kolya.gerasimenko.96@mail.ru
physician at the Institute of Urology and Reproductive Health Moscow, Russia

P. Glybochko

FGAOU VO I.M. Sechenov First Moscow State Medical Universit

Email: rector@sechenov.ru
Academician of the RAS, professor, Ph.D., MD, Director of Institute of Urology and Reproductive Health Moscow, Russia

Әдебиет тізімі

  1. Чиссов В.И., Алексеева Б.Я., Русакова И.Г. Онкоурология. Национальное руководство. М.: ГЭОТАР-Медиа. 2012;688 с.
  2. Chang S.S., Gaudin P.B., Reuter V.E., Heston W.D.W. Prostate-specific membrane antigen: Present and future applications. Urology. 2000;55(5):622-629. doi: 10.1016/s0090-4295(99)00600-7.
  3. Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol. 2005;16(3):481-488. doi: 10.1093/annonc/mdi098. PMID: 15718248.
  4. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ НМИРЦ Минздрава России, 2017;12-36 с.
  5. Велиев Е.И., Соколов Е.А., Лоран О.Б. Улучшение рецидивной выживаемости после радикальной простатэктомии при местно-распространенном раке предстательной железы в зависимости от срока оперативного вмешательства. Онкоурология. 2016;1(12):69-73. Doi.10.17650/1726-9776-2016-12-1-69-73.
  6. Пушкарь Д.Ю. Радикальная простатэктомия. М.: МЕДпресс-информ. 2002;168 с.
  7. Abdollah F., Sun M., Schmitges J., et al. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. J. Urol. 2012;188:73-83. doi: 10.1016/j.juro.2012.03.005.
  8. Augustin H., Hammerer P., Graefen M. Intraoperative and perioperative morbidity of contemporary radical retropubic prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur. Urol. 2003;43(2):113-18. doi: 10.1016/s0302-2838(02)00495-5.
  9. Petrov S.B., Veliev E.I. Surgical treatment of localized prostate cancer. Prakt. onkologiya. SPb.: RMZH. 2001 ;2(6):50-52. Russian (Петров С.Б., Велиев Е.И. Хирургическое лечение локализованных форм рака предстательной железы. Практ. онкология. СПб.: РМЖ. 2001;2(6):50-52).
  10. Isbarn H., Wanner M., Salomon G., et al. Long-term data on the survival of patients with prostate cancer treated with radicai prostatectomy in the prostate-specific antigen era. BJU Int. 2010;106(1):37-43. doi: 10.1111/j.1464-410X.2009.09134.x.
  11. Porter C.R., Kodama K., Gibbons R.P., et. al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. Urol. 2006;176(2):569-574. doi: 10.1016/j.juro.2006.03.094.
  12. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et. al. Dose-response in radiotherapy for iocaiized prostate cancer: resuits of the Dutch muiticenter randomized phase III triai comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncoi. 2006;24(13):1990-1996. doi: 10.1200/JCO.2005.05.2530.
  13. Pereverzev A.C., Kogan M.I. Prostate cancer. Khar'kov: Fakt. 2004;231 p. Russian (Переверзев A.C., Коган М.И. Рак простаты. Харьков: Факт. 2004;231 с.).
  14. Соловов В.А., Орлов А.Е., Воздвиженский М.О. и др. Высокоинтенсивная фокусированная ультразвуковая аблация (HIFU) рака предстательной железы у 976 пациентов: 7-летние результаты. Известия Самарского научного центра Российской академии наук. 2015;2(3):682-685.
  15. Nguyen D.P., Giannarini G., Seailer R et al. Locai recurrence after retropubic radicai prostatectomy for prostate cancer does not exciusiveiy occur at the anastomotic site. BJU Int. 2013;112(4):E243-49. doi: 10.1111/j.1464-410X.2012.11506.x.
  16. Черняев В.А., Матвеев В.Б., Волкова М.И., и др. Факторы прогноза биохимического рецидива локализованного и местно-распространенного рака простаты после радикальной простатэктомии. Онкоурология. 2012;4:58-64. doi: 10.17650/1726-9776-2012-8-4-58-64.
  17. Babaian R.J., Troncoso P., Bhadkamkar V.A., Johnston D.A. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001;91(8):1414-1422.
  18. Горбань Н.А., Капякин А.О. Факторы прогноза при раке предстательной железы. Онкоурология. 2010;4:47-54. Doi. 10.17650/1726-9776-2010-6-4-47-53).
  19. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005;29(9):1228- 1242. doi: 10.1097/01.pas.0000173646.99337.b1.
  20. Carvalhal G.F., Humphrey P.A., Thorson P., et. all. Visuale estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer. 2000;89(6): 1308-1314. Doi. 10.1002/1097-0142(20000915)89:6<1308::aid-cncr16>3.0.co;2-3.
  21. Blute M.L., Bergstralh E.J. el al. Use of Gleason score, prostatespecific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001;165:119-125. doi: 10.1097/00005392-200101000-00030.
  22. Грицкевич А.А., Медведев В.Л., Костин А.А., Русаков И.Г. Прогностические факторы выживаемости больных при раке предстательной железы. М.: Экспериментальная и клиническая урология. 2017;4:12-19.
  23. Лачинов Э.Л. Диагностика и прогнозирование местного рецидива рака простаты после радикальной простатэктомии с использованием магнито-резонансной томографии. Автореферат диссертация кандидата мед. наук. М. 2014; 23 с.
  24. McNeal J.E., Villers A.A., Redwine E., et. all. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am. J. Surg. Pathol. 1990;14(3):240-247. doi: 10.1097/00000478-199003000-00005.
  25. Greene D.R., Wheeler T.M., Egawa S., et. all. A Comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 1991 ; 146(4): 1069-1076. doi: 10.1016/s0022-5347(17)38003-5.
  26. Gilbert S.M., Cavallo C.B., Kahane H., et. all. Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65(3):549-553. Doi: 10.1016/j. urology.2004.10.064.
  27. Шатов А.В., Березуцкий М.В., Струков М.В. Применение низкопольной магнитно-резонансной томографии в комплексе лучевой диагностики заболеваний предстательной железы. Урол. и нефрол. 1996;(5):33-37.
  28. Catalona W.J., Smith D.S. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediateterm results. J. Urol. 1998;160(6):2428-2434. doi: 10.1097/00005392-199812020-00012.
  29. Ito K., Nakashima J., Mukai M., et. all. Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy. Urol. Int. 2003;70(4):297-302. doi: 10.1159/000070139.
  30. Wheeler T.M., Dillioglugil O., Rattan M.W., et. all. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage Tl-2 prostate cancer. Hum. Pathol. 1998;29(8):856-862. doi: 10.1016/s0046-8177(98)90457-9.
  31. Велиев Е.И. Оптимизация хирургического лечения больных локализованным раком предстательной железы. Автореферат диссертация доктора мед. наук. СПб. 2003;40 с.).
  32. D’Amico A.V., Whittington R., Malkowicz S.B., Schultz D. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score 10.1002/(sici)1097-0142(20000501)88:9<2110::aid-cncr17>3.0.co;2-e.
  33. Epstein J.I. Surgical margins in patients with carcinoma of the prostate. AUA Update Series. 1994;8(7):53-59.
  34. Epstein J.I., Pizov G., Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;7(71):3582- 3593. Doi: 10. 1002/1097-0142( 19930601 )71: 11 № 3582 : :aid-cncr2820711120>3.0.co;2-y
  35. Blute M.L., Bergstralh E.J., el al. Use of Gleason score, prostatespecific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J. Urol. 2001;165:119-125. doi: 10.1097/00005392-200101000-00030.
  36. Ikonen S., Karkkainen P., Kivisaari L., et al. Magnetic resonance imaging of prostatic cancer: does detection vary between high and low gleason score tumors? The Prostate. 2000;43(1):43-48. doi: 10.1002/(sici)1097-0045(20000401)43:1<43::aid-pros6>3.0.co;2-s.
  37. Salomon L., Anastasiadis A.G., Antiphon P., et al. Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol. Int. 2003;70(4):491-496. doi: 10.1159/000070138.
  38. Gleason D.F. Histologic grading of prostate cancer - a perspective. Hum. Pathol. 1992;23(3):273-279. doi: 10.1016/0046-8177(92)90108-f.
  39. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2005;29(9):1228- 1242. doi: 10.1097/01.pas.0000173646.99337.b1.
  40. Smith J.A. Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases at Montsouris Institute. Urol. Oncol. 2003;21(6):480-481.
  41. Villers A.A., McNeal J.E., Redwine E., et. all. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J. Urol. 1989;142(3):763-768. doi: 10.1016/s0022-5347(17)38881-x.
  42. Пушкарь Д.Ю., Бормотин А.В. Уточнение стадии рака предстательной железы после радикальной простатэктомии. М.: Урология 2003;(3):11-14.
  43. Maru N., Ohori M., Kattan M.W., et. all. Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum. Pathol. 2001;32(8):828-833. doi: 10.1053/hupa.2001.26456.
  44. Katz B., Srougi M., Dall’oglio M., et. all. Perineural invasion detection in prostate biopsy is related to recurrence-free survival in patients submitted to radical prostatectomy. Urologic Oncology. 2013;31(2):175-179. doi: 10.1016/j.urolonc.2010.11.008.
  45. Herman C.M., Wilcox G.E., Kattan M.W., et. all. Lymphovascular invasion as a predictor of disease progression in prostate cancer. Am. J. Surg. Pathol. 2000;24(6):8598-8563. doi: 10.1097/00000478-200006000-00012.
  46. De la Taille A., Rubin M.A., Buttyan R., et. all. Is microvascular invasion on radical prostatectomy specimen a useful predictor of PSA recurrence for prostate cancer patients? Eur. Urol. 2000;2:134-136. doi: 10.1159/000020256.
  47. Yee D.S., Shariat S.F., Lowrance W.T., et. all. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. BJU Int. 2011;108(4):502-507. doi: 10.1111/j.1464-410X.2010.09848.x.
  48. Roberts W.W., Bergstralh E.J., Blute M.L., et. all. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. 2001;57(6):1033-1037. doi: 10.1016/s0090-4295(01)00978-5.
  49. Baydar D.E., Baseskioglu B., Ozen H., Geyik P.O. Prognostic significance of lymphovascular invasion in clinically localized prostate cancer after radical prostatectomy. Scientific World Journal. 2008;8:303-312. Doi: 10.1100/ tsw.2008.49.
  50. Zhou M., Hayasaka S., Taylor J.M., et. all. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy. J. Urol. 2001;166(6):2193-2198.
  51. Djavan B., Moul J.W., Zlotta A., et. all. PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol. 2003;43(l):12-27. doi: 10.1016/s0302-2838(02)00505-5.
  52. Rouviere O., Vitry T., Lyonnet D. Imaging of prostate cancer local recurrences: why and how? Eur. Radiol. 2010;20(5):1254-1266. doi: 10.1007/s00330-009-1647-4.
  53. Amling C.L., Bergstralh E.J., Blute M.L., et. all. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J. Urol. 2001;165(4):1146-1151.
  54. Grossfeld G.D., Latini D.M., Lubeck D.P., et. all. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. Hi. Urol. 2003;169(1):157-63. doi: 10.1016/s0090-4295(01)01658-2.
  55. Kausik S.J., BluteM.L., Sebo T.J., et. all. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer. 2002;95(6):1-12. doi: 10.1002/cncr.10871.
  56. Koppie T.M., Grossfeld G.D., Nudell D.M., et. all. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J. Urol. 2001;166(1)111-115.
  57. Cronin A.M., Godoy G., Vickers A.J. Definition of biochemical recurrence after radical prostatectomy does not substantially impact prognostic factor estimates. Urol. 2010;183(3):984-989. doi: 10.1016/j.juro.2009.11.027.
  58. Han M., Partin A. W., Zahurak M., et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003;169(2):517-25. doi: 10.1097/01.ju.0000045749.90353.c7.
  59. Briganti A., Karnes R.J., Joniau S., et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. 2014;66(3):479-486. Doi: 10.1016/j. eururo.2013.11.045.
  60. Brockman J.A., Alanee S., Vickers A.J., et al. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. Eur Urol. 2015;67(6):1160-1167. Doi: 10.1016/j. eururo.2014.09.019.
  61. Гервас П.А., Литвяков Н.В., Попова Н.О., и др. Проблемы и перспективы совершенствования молекулярно-генетической диагностики для назначения таргетных препаратов в онкологии. Сибирский онкологический журнал. 2014;2:46-55.
  62. Вторушин С.В., Безгодова Н.В., Плешкунов А.А. Молекулярно-биологические факторы прогноза при раке предстательной железы. Сибирский онкологический журнал. 2017;16(1):82-90. Doi. 10.21294/1814-4861-2017-16-1-82-90.
  63. Zincke H., Osterling J.E., Blute M.L. et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850-1857. doi: 10.1016/s0022-5347(17)32399-6.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2021

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>